HF
NAGE

HRT Financial’s Niagen Bioscience NAGE Stock Holding History

HRT Financial’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-130,845
Closed -$455K – 3290
2024
Q1 		$455K Buy
130,845
+118,243
+938% +$219K ﹤0.01% 1318
2023
Q4 		$18K Buy
+12,602
New +$17.6K ﹤0.01% 2046
2023
Q3 		– Sell
-17,745
Closed -$27K – 3249
2023
Q2 		$27K Buy
+17,745
New +$26.5K ﹤0.01% 2074
2022
Q3 		– Sell
-37,787
Closed -$63K – 3635
2022
Q2 		$63K Buy
+37,787
New +$73.9K ﹤0.01% 2488
2020
Q4 		– Sell
-10,575
Closed -$42K – 2588
2020
Q3 		$42K Buy
+10,575
New +$51K ﹤0.01% 1705

Other funds holding NAGE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return

HRT Financial's NAGE Position: Q2 2024 in Review

HRT Financial sold out of Niagen Bioscience (NAGE) in Q2 2024, closing a stake of 130,845 shares — an estimated $455K sold.

HRT Financial first reported a position in NAGE in Q3 2020 and held it in 5 quarters. The position peaked at $455K in Q1 2024. 78 funds tracked by Wall St. Rank hold NAGE as of Q2 2024.

  • HRT Financial reported no remaining Niagen Bioscience position as of Q2 2024 after selling out during the quarter.
  • HRT Financial sold 130,845 Niagen Bioscience shares in Q2 2024, an estimated $455K.
  • HRT Financial first reported a position in Niagen Bioscience in Q3 2020 and held it in 5 quarters.
  • HRT Financial's Niagen Bioscience position peaked at $455K in Q1 2024.
  • 78 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2024.

Based on HRT Financial's 13F filing for Q2 2024, filed 12 Aug 2024.